Effect of dexmedetomidine on blood loss and patient outcomes in orthognathic surgery
Phase 4
Completed
- Conditions
- orthognathic surgery patientsdexmedetomidine, blood loss, orthognathic surgery
- Registration Number
- TCTR20230818002
- Lead Sponsor
- self support
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1. patient undergoing bimaxillary orthognathic surgery
2. ASA classification 1 or 2
Exclusion Criteria
1. patient with coagulopathy
2. patient with bradycardia, cardiac dysrhythmias
3. known allergy to the study drugs
4. pregnancy and lactation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain dexmedetomidine's effect on blood loss in orthognathic surgery?
How does dexmedetomidine compare to standard anesthetics in reducing postoperative blood loss in orthognathic surgery patients?
Are there specific biomarkers that predict orthognathic surgery patient response to dexmedetomidine treatment?
What are the known adverse events associated with dexmedetomidine use in orthognathic surgery and how are they managed?
What combination therapies or alternative drugs show promise in managing blood loss during orthognathic surgery compared to dexmedetomidine?